After a preliminary analysis showed the drug to be 90% effective, there was an uproar among a section of scientists. AstraZeneca executives later said that high-efficacy dosage was an outcome of a dosing error. India is heavily relying on the success of AstraZeneca's vaccine for a faster rollout.